Mood Stabilizer-induced Metabolic Abnormalities in Bipolar Disorder
Status:
Recruiting
Trial end date:
2021-07-01
Target enrollment:
Participant gender:
Summary
The potential effects of microbiota in bipolar disorder (BD) with microbiota-related
dysfunction have not yet been explored clinically, and the integration of microbiota and
pharmacometabolomic approaches can provide us the identification of the significant effects
of mood stabilizers on metabolic homeostasis, treatment response, and cognitive performance.
Therefore, we propose to develop the integration of the microbiota and pharmacometabolomics
knowledge base about the mood stabilizer-induced metabolic abnormalities in BD patients.